// App-Quantinova.ai

780 : The Novel CXCR4 Antagonist POL5551 Decreases Surface CXCR4 (s-CXCR4) Expression, Inhibits Chemotaxis, and Enhances Chemosensitivity in Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Daniel Magoon

Principal Investigators

  • Eric Chevalier

  • Klaus Dembowsky

  • Patrick Brown

Medical Centers

  • Pediatric Oncology, Johns Hopkins University, Baltimore, MD, USA,

Locations

  • United States

Companies

  • Polyphor Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Acute Leukemia

Biomarkers

  • Annexin V

  • Breakpoint Cluster Region

  • Nucleoside diphosphate kinase A

  • Cancer antigen 15-3

  • Stromal cell-derived factor 1

Drug/Treatment

  • Daunorubicin

  • Plerixafor

  • POL5551

  • CXCL12

  • SDF-1

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved